Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2012 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Long-Term Deferred Tax of $907.0 million for Q1 2026, up 57.71% year-over-year from $575.1 million in Q1 2025, and up 4.36% quarter-over-quarter from $869.1 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2012 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Long-Term Deferred Tax history runs 15 years deep, the most recent figure standing at $907.0 million for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax rose 57.71% year-over-year to $907.0 million; the TTM figure through Mar 2026 stood at $907.0 million (up 57.71% YoY), while the FY2025 annual figure was $869.1 million, up 55.13% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $907.0 million, up from $869.1 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $907.0 million in Q1 2026, with the low at $314.7 million in Q1 2022.
- The 5-year median for Long-Term Deferred Tax is $507.7 million (2024), against an average of $535.0 million.
- The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax grew 0.1% in 2022, then soared 57.71% in 2026.
- Jazz Pharmaceuticals' Long-Term Deferred Tax stood at $376.2 million in 2022, then advanced by 27.0% to $477.8 million in 2023, then increased by 17.25% to $560.2 million in 2024, then jumped by 55.13% to $869.1 million in 2025, then rose by 4.36% to $907.0 million in 2026.
- Business Quant data shows JAZZ's Long-Term Deferred Tax at $907.0 million in Q1 2026, $869.1 million in Q4 2025, and $846.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 926.40 Mn |
| Mar 31, 2026 | 907.00 Mn |
| Dec 31, 2025 | 869.10 Mn |
| Sep 30, 2025 | 846.17 Mn |
| Jun 30, 2025 | 602.90 Mn |
| Mar 31, 2025 | 575.10 Mn |
| Dec 31, 2024 | 560.25 Mn |
| Sep 30, 2024 | 583.22 Mn |
| Jun 30, 2024 | 545.22 Mn |
| Mar 31, 2024 | 507.75 Mn |
| Dec 31, 2023 | 477.83 Mn |
| Sep 30, 2023 | 464.37 Mn |
| Jun 30, 2023 | 430.09 Mn |
| Mar 31, 2023 | 399.10 Mn |
| Dec 31, 2022 | 376.25 Mn |
| Sep 30, 2022 | 314.97 Mn |
| Jun 30, 2022 | 320.55 Mn |
| Mar 31, 2022 | 314.67 Mn |
| Dec 31, 2021 | 311.10 Mn |
| Sep 30, 2021 | 314.67 Mn |